?Administrative Core Gary D.V. Hankins, MD, will be the director, and Mahmoud S. Ahmed, PhD, will be the associate director for the proposed center. The director and associate director have worked together during the last 10 years in their capacity as the clinical and translational PIs of the OPRU at UTMB. They will continue to work together in the OPRC and have active roles as mentors and advisors to the lead investigators in their respective areas of expertise. The administrative core will include the director, associate director, Dr. Holly West as the senior research coordinator, Dr. Mahbubur Rahman as the statistician, and Dr. Wayne Snodgrass as the clinical pharmacologist and education/ training coordinator. They will be assisted by Mrs. Sanchez-Martinez. The administrative core will have an oversight committee composed of 4 scientists with administrative experience. They will be supported by the business office, grant and media support office, pre- and postaward accounting office, and human resources of the Ob/Gyn department. The majority of administrative issues within UTMB will be managed by Dr. Ahmed while communications with other OPRC centers, the steering committee, and the logistic coordinating core will be managed by Dr. Hankins. There are 3 major goals/ specific aims for the administrative core, namely (1) ensure that the clinical and translational infrastructures provide the necessary support for the researchers, (2) streamline communications between the investigators and other personnel to provide the time needed for the lead investigators to focus on achieving the goals of their projects, (3) provide education, training, and mentorship for junior investigators, and recruit individuals interested in a career in obstetric-fetal pharmacology. Ultimately, the administrative core will ensure that the center will achieve its primary goal of making more medications and biologics available for treatment of the pregnant patient and fetus.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54HD047891-12
Application #
9119185
Study Section
Special Emphasis Panel (ZHD1)
Project Start
Project End
Budget Start
2016-07-01
Budget End
2017-06-30
Support Year
12
Fiscal Year
2016
Total Cost
Indirect Cost
Name
University of Texas Medical Br Galveston
Department
Type
DUNS #
800771149
City
Galveston
State
TX
Country
United States
Zip Code
77555
Speidel, Jordan T; Xu, Meixiang; Abdel-Rahman, Sherif Z (2018) Bisphenol A (BPA) and bisphenol S (BPS) alter the promoter activity of the ABCB1 gene encoding P-glycoprotein in the human placenta in a haplotype-dependent manner. Toxicol Appl Pharmacol 359:47-54
Speidel, Jordan T; Xu, Meixiang; Abdel-Rahman, Sherif Z (2018) Promoter Haplotypes of the ABCB1 Gene Encoding the P-Glycoprotein Differentially Affect Its Promoter Activity by Altering Transcription Factor Binding. DNA Cell Biol 37:973-981
Shah, Mansi; Bourner, Luke; Ali, Shariq et al. (2018) HPLC Method Development for Quantification of Doxorubicin in Cell Culture and Placental Perfusion Media. Separations 5:
Speidel, Jordan T; Xu, Meixiang; Abdel-Rahman, Sherif Z (2018) Differential effect of ABCB1 haplotypes on promoter activity. Pharmacogenet Genomics 28:69-77
Al-Enazy, Sanaalarab; Ali, Shariq; Albekairi, Norah et al. (2017) Placental control of drug delivery. Adv Drug Deliv Rev 116:63-72
Marrs, Caroline C; Costantine, Maged M (2017) Should We Add Pravastatin to Aspirin for Preeclampsia Prevention in High-risk Women? Clin Obstet Gynecol 60:161-168
Gopalakrishnan, Kathirvel; More, Amar S; Hankins, Gary D et al. (2017) Postnatal Cardiovascular Consequences in the Offspring of Pregnant Rats Exposed to Smoking and Smoking Cessation Pharmacotherapies. Reprod Sci 24:919-933
Shah, Mansi; Bourner, Luke; Ali, Shariq et al. (2017) Cytotoxicity of Endocytosis and Efflux Inhibitors in the BeWo Cell Line. J Pharm Res Int 17:
Costantine, Maged M; Cleary, Kirsten; Hebert, Mary F et al. (2016) Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: a pilot randomized controlled trial. Am J Obstet Gynecol 214:720.e1-720.e17
Costantine, Maged M; Ananth, Cande V (2016) The early developments of preeclampsia drugs. Expert Opin Investig Drugs 25:867-70

Showing the most recent 10 out of 14 publications